Global Protein Therapeutics Market Research Report 2022: Focus on Insulin; fusion protein; Erythropoietin; interferon; Human Growth Hormone; Follicle Stimulating Hormone –

DUBLIN–(BUSINESS WIRE)–The report “Global Protein Therapeutics Market Report 2022: By Product, By Application, By Function” has been added to from offer.

The global therapeutic protein market is expected to grow from $100.06 billion in 2021 to $112.17 billion in 2022 at a compound annual growth rate (CAGR) of 12.1%. The market is expected to reach $177.30 billion in 2026 with a CAGR of 12.1%.

The therapeutic proteins market consists of the sale of therapeutic proteins. Therapeutic proteins provide important therapies for diseases such as diabetes, cancer, infectious diseases, hemophilia and anemia.

The major product types in Therapeutic Proteins are Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. Insulin is a peptide hormone produced by beta cells in pancreatic cells which serves as the primary anabolic hormone of the individual. It affects the metabolism of fats, carbohydrates and proteins by stimulating the uptake of glucose from the blood into fat, liver and skeletal muscle cells.

The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, protein diagnostics and are used in various applications such as metabolic disorders, immunological disorders, hematological disorders, cancer, disorders hormonal, genetic disorders, etc.

Advanced technologies for protein drug development are driving the protein therapeutics market. Therapeutic proteins cannot be synthesized chemically, they must be produced by genetic engineering and recombinant DNA technology in living cells or organisms.

Protein engineering platform technologies such as glycoengineering, pegylation, Fc fusion, albumin fusion, albumin-drug conjugation help to increase production yield, product purity, Circulating half-life, targeting and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, recombinant human coagulation factor IX are therapeutic protein drugs developed using FDA-approved protein engineering technologies over the past five years.

The rise of biosimilar drugs in the global market is slowing down the growth of the therapeutic protein market. The expiration of patents for therapeutic proteins such as monoclonal antibodies paves the way for the entry of biosimilars. In the EU, AbbVie highlighted the patent expiration of Humira (adalimumab) in 2018, five Humira biosimilars from Mylan, Amgen, Sandoz, Samsung Bioepis received drug approvals from the European Commission to enter on the EU market. These cost-effective treatments similar to the original biologics decrease revenues and sales of therapeutic proteins.

Monoclonal antibody drug approvals are on the rise in the protein therapeutics segment. Chronic diseases such as cancer, immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established class of products in the protein therapeutic segment with more safety and immunogenicity than antibodies.

Cell-based expression systems such as the Chinese Hamster Ovary (CHO) mammalian cell expression system with the latest technologies have increased the productivity of monoclonal antibodies by overcoming the problems associated with earlier antibody drugs. Over the past five years, the FDA has approved 213 drugs, 44 of which are monoclonal antibodies. For example, twelve monoclonal antibodies have been approved by the FDA for the treatment of cancer and immunological disorders.

In the United States, manufacturers of therapeutic protein drugs file a therapeutic biologics application (BLA) with the FDA for product approval. The BLA-approved drug must be proven to be safe, pure, and potent. FDA Consolidated Review of Most Therapeutic Proteins in the Center for Drug Evaluation and Research (CDER). In the European Union, biological products are regulated by the Committee for Medicinal Products for Human Use (CHMP) for marketing authorization.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies Inc. for $1 billion. Lilly is excited to add breakthrough protomer technology to its diabetes pipeline with this acquisition, as the company’s glucose-sensing insulin program, which is based on its proprietary sensor molecular engineering platform of proteins (MEPS), has great potential.

The major players in the therapeutic proteins market are

  • Abbott Laboratories

  • Amgen Inc.

  • Baxter International Inc.

  • Eli Lilly and company

  • F.Hoffmann-La Roche Ltd.

  • Pfizer Inc.

  • Johnson & Johnson

  • Merck & Co Inc.

  • Novo Nordisk A/S

  • Sanofi

  • Biogene Inc.

  • Genentech inc.

  • Genex Biotechnology

  • Genetech

  • Merck Serono S.A.

  • Astra Zeneca

  • Boehringer Ingelheim

  • Pharmaceutical Chugai

  • Diasome Pharmaceuticals

  • GeneScience Pharmaceuticals

  • Hualan Biological Engineering

  • CSL Behring

  • Kyowa Hakko Kirin

  • Oramed Pharmaceuticals

  • Sandoz International

  • Teva Pharmaceutical Industries

  • AbbVie

  • Bristol Myers Squibb Co.

  • Novartis

  • ProBiogen SA

Main topics covered:

1. Summary

2. Characteristics of Therapeutic Proteins Market

3. Protein Therapeutics Market Trends and Strategies

4. Impact of COVID-19 on Therapeutic Proteins

5. Protein Therapeutics Market Size and Growth

5.1. Global Historical Protein Therapeutics Market, 2016-2021, USD Billion

5.1.1. Market Drivers

5.1.2. Market Constraints

5.2. Global Protein Therapeutics Market Forecast, 2021-2026F, 2031F, Billion USD

5.2.1. Market Drivers

5.2.2. Market Constraints

6. Protein Therapeutics Market Segmentation

6.1. Global Therapeutic Proteins Market, Segmentation by Product Type, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Insulin

  • Fusion Protein

  • Erythropoietin

  • Interferon

  • human growth hormone

  • follicle stimulating hormone

6.2. Global Protein Therapeutics Market, Segmentation by Application, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Metabolic disorders

  • Immunological disorders

  • Hematological disorders

  • Cancer

  • Hormonal disorders

  • Genetic Disorders

  • Others

6.3. Global Protein Therapeutics Market, Segmentation by Function, History and Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

  • Enzymatic and regulatory activity

  • Special targeting activity

  • Vaccines

  • Protein diagnostics

7. Regional and Country Analysis of Protein Therapeutics Market

7.1. Global Protein Therapeutics Market, Split by Region, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, Billion USD

7.2. Global Protein Therapeutics Market, Split by Country, Historical & Forecast, 2016-2021, 2021-2026F, 2031F, USD Billion

For more information about this report visit

Comments are closed.